Similar to recent studies on dual ferroptosis inducers, the dual-targeting strategy is consistent with the emerging paradigm of combinatorial targeting to overcome compensatory mechanisms.32 Furthermore, artemisinin derivatives have demonstrated efficacy in eradicating oxaliplatin-resistant CRC cells through ferroptosis, thereby underscoring the potential of ferroptosis in combating drug resistance.11,40 Currently, the upregulation of HO-1 is one of the strategies used to increase Fe2+ levels, but the role of HO-1 in ferroptosis has been controversial. The gene discussed is HMOX1; the disease is colorectal carcinoma.